In this study, we have proven that berberine enhanced the activity of erlotinib and cetuximab in vitro and in vivo by inhibiting the EGFR/STAT3 signaling pathway, which suggests a potential role for berberine in the treatment of GC, particularly in combination with EGFR-TKIs therapy. The gene discussed is STAT3; the disease is gastric cancer.